OGN (Organon) Tariff Resilience Score: 7/10 (As of Jun. 29, 2026)


OGN Organon & Co OGN
71 GF Score
Price $13.51
GF Value $14.55
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Organon Tariff Resilience Score?

Organon OGN +0.04% 71 Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Organon ranks better than 97.08% on this metric.

Organon has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Organon has Organon & Co has a global pharmaceutical supply chain but benefits from industry-specific exemptions. Its diverse product range and ability to shift production locations enhance resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Organon might have Highly Resilient.

Organon  (NYSE:OGN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Organon Tariff Resilience Score Related Terms

OGN vs AMRN, SCLX, MIRA: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Organon's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organon Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Organon's Tariff Resilience Score falls into.


OGN
71GF Score
Organon & Co OGN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Organon (OGN) has a Tariff Resilience Score of 7 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Organon ranks #30 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Organon's Tariff Resilience Score too high?
Organon's current Tariff Resilience Score is 7. Based on the distribution chart, Organon ranks #30 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Tariff Resilience Score compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #30 out of 1028 companies for Tariff Resilience Score. This places Organon in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Organon's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.51 — trading 7.2% below its estimated fair value. The current Tariff Resilience Score is 7. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Organon (OGN), the current Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of $13.51 is trading 7.2% below its estimated GF Value™ of $14.55. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Tariff Resilience Score: 7
  • GF Value™: $14.55 vs. price of $13.51 (7.2% below fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score

Get the complete analysis for OGN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.51
Price
$14.55
GF Value